Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving <sup>225</sup>Ac-PSMA-617 Radioligand Therapy.

导出原文传递

翻译打印收藏纠错

第一作者： Mike,Sathekge

第一单位： Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa mike.sathekge@up.ac.za.

作者： Mike,Sathekge ^[1] ; Frank,Bruchertseifer ^[2] ; Mariza,Vorster ^[3] ; Ismaheel O,Lawal ^[3] ; Otto,Knoesen ^[4] ; Johncy,Mahapane ^[3] ; Cindy,Davis ^[3] ; Florette,Reyneke ^[3] ; Alex,Maes ^[3] ; Clemens,Kratochwil ^[5] ; Thabo,Lengana ^[6] ; Frederik L,Giesel ^[3] ; Christophe,Van de Wiele ^[6] ; Alfred,Morgenstern ^[3]

作者单位： Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa mike.sathekge@up.ac.za. ^[1] European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany. ^[2] Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa. ^[3] Nuclear Technology Products (NTP), Pelindaba, South Africa. ^[4] Katholieke University Leuven, Kortrijk, Belgium. ^[5] University Hospital Heidelberg, Heidelberg, Germany; and. ^[6] Ghent University, Ghent, Belgium. ^[7]

关键词 225Ac PSA response PSMA prostate carcinoma radioligand therapy